Systemic Interventions Targeting Epidermal Barrier Function: Translational Insights from Oral Probiotics.

The epidermal barrier is increasingly recognized as a dynamic and pharmacologically targetable system that extends beyond its traditional role as a passive structural defense. In inflammatory skin diseases such as atopic dermatitis and psoriasis, barrier dysfunction contributes not only to increased permeability and environmental susceptibility but also to complex bidirectional interactions involving immune dysregulation, microbial imbalance, oxidative stress, and systemic inflammation. Emerging evidence further supports the concept of the gut-skin axis as a systemic regulatory network linking intestinal microbiota, microbial metabolites, immune signaling, and epidermal homeostasis. Microbiota-derived metabolites, including short-chain fatty acids and aryl hydrocarbon receptor-related microbial metabolites, have been implicated in the regulation of keratinocyte differentiation, lipid metabolism, and epithelial integrity. Within this framework, oral probiotics have attracted increasing attention as biologically plausible systemic modulators of skin barrier function. Experimental and translational studies suggest that probiotics may improve transepidermal water loss, barrier-associated protein expression, inflammatory signaling, and microbial homeostasis through immune and metabolic mechanisms. However, current evidence remains heterogeneous because of strain-specific variability, inconsistent study methodologies, and limited standardized barrier-associated endpoints. Consequently, the clinical utility of microbiome-targeted therapy remains substantially stronger at the mechanistic and preclinical level than at the level of standardized large-scale clinical validation. Current evidence is also considerably more developed in atopic dermatitis than in psoriasis and other inflammatory dermatoses. Future progress will likely depend on integrated multi-omics analyses, functional barrier phenotyping, host-genetic stratification, and longitudinal therapeutic monitoring to enable precision barrier-centered interventions and personalized dermatologic strategies.